Category: biotech

.Pro equity capital agency venBio has actually lifted another half a billion dollars to buy biotechs focusing on diseases with unmet need. The $528 million

.After introducing a phase 3 launch based upon positive midstage results, iTeos and also GSK are actually lastly discussing the highlights coming from the stage

.Otsuka Pharmaceutical’s renal health condition drug has reached the main endpoint of a period 3 test through displaying in an interim study the reduction of

.Zevra Rehabs’ rare illness medicine seems to become on the road to approval this fall after gaining the support of an FDA advising committee, although

.Bicara Therapies and Zenas Biopharma have given clean inspiration to the IPO market with filings that highlight what newly public biotechs may seem like in

.CEO David Ricks can easily observe the companies establishing outdoors tents at basecamp responsible for Eli Lilly in an effort to acquire a footing of

.After bring up $213 thousand in 2023– one of the year’s largest private biotech rounds– Tome Biosciences is creating reduces.” Regardless of our clear scientific

.As biotechs attempt to switch a fresh web page in August, at least 3 business have dropped team in attempts to shape on. First up

.OncoC4 is taking AcroImmune– as well as its own in-house professional production abilities– under its wing in an all-stock merger.Both cancer cells biotechs were actually

.Zephyrm Bioscience is actually gusting towards the Hong Kong stock market, filing (PDF) for an IPO to stake phase 3 trials of its own cell